World's First Real-Time Monitoring System for Ablation Procedures

Projektinformationen

BioTrace

ID Finanzhilfevereinbarung: 889397

DOI

10.3030/889397

Projekt abgeschlossen

EK-Unterschriftsdatum 4 November 2019

Startdatum 1 Dezember 2019

Enddatum 30 April 2020

Finanziert unter

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Gesamtkosten

€ 71 429,00

EU-Beitrag

€ 50 000,00

Koordiniert durch

TECHSOMED MEDICAL TECHNOLOGIES LTD
Israel

Periodic Reporting for period 1 - BioTrace (World's First Real-Time Monitoring System for Ablation Procedures )

Berichtszeitraum: 2019-12-01 bis 2020-04-30

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

Thermal ablation (TA) is an attractive treatment for oncology, heart arrhythmias or chronic pain. It offers shorter hospital stays, faster recovery and less complications than surgery. However, specialists are blind regarding target tissue destruction or collateral damage and high failure rates (e.g. recurrence) or overtreatment are common. TechsoMed has developed BioTrace™, the first real-time monitoring and control software for ablation. It interfaces with ultrasound devices to provide AI-guided image analysis and accurate prediction of tissue damage after 24 hrs (done today with CT or MRI). It has been initially validated for liver tumor ablation (oncology) and now it needs to be optimized and exhaustively validated in clinical trials to reach certification in Europe (CE), USA (FDA) and Japan (PMDA). Other applications of the system (e.g. cardiovascular TA) will gradually scale-up the technology. For market deployment, robust partnerships with ultrasound/ablation devices manufacturers (currently Phillips, GEH, Siemens or J&J.) need to be established.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

TechsoMed's core know-how was developed at Sheba Medical Center (Israel). The company transformed it from concept to a working prototype of the BioTrace™ system. The application for liver tumors is the most advanced, with a clinical study completed in 54 patients from Sheba Medical Center and University of Tokyo Hospital (Japan). Compared with 24 hrs post-treatment CT scans (a gold standard), the system shows a consistent >92% matching. BioTrace™ has been patented and the regulatory roadmap is progressing, with FDA approval process initiated. The feasibility study has allowed to plan further steps, calculate financial needs of the project and quantify the business opportunity for the company.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

In ablation, ultrasound (US) or computed tomography (CT) provide good visualization and control during probe placement, but do not offer in situ monitoring. Moreover, current treatment planning neglects patient-specific parameters that influence ablation zone morphology. BioTrace™ allows to use US imaging to monitor TA procedure in real time and accurately predict tissue damage as it evolves over 24 hrs post procedure, to reach optimal outcomes in target tissue destruction with minimal adjacent damage. Enhancing TA results and avoiding recurrence or complications can help to boost the use of this minimally invasive technique and bring multiple benefits to patients, hospitals and healthcare systems globally.

Company logo